Refine by
Biological Research Articles & Analysis
219 news found
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is excited to announce the launch of its new Immune System Tissue Microarrays for the scientific community to study the complex interactions of the immune system in various tissues. These innovative products offer researchers a powerful tool to unravel the complexities of the immune system and ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is pleased to announce the launch of its new line of Circulatory System Tissue Microarrays to the scientific community. This new product line offers researchers a powerful tool to study a wide range of diseases affecting the heart, blood vessels, and spleen. CD BioSciences is committed to ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA. As CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells are the most ...
CD Formulation, a leading pharmaceutical contract service company, has recently unveiled groundbreaking hydrogel microneedle patch technology aiming at increase the drug loading capacity and enhance drug delivery efficiency. The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. The mechanistic Target of Rapamycin is a serine/threonine protein kinase that is inhibited by rapamycin, a bacterial compound originally isolated from Easter Island soil that ...
With the development of tissue transparency techniques and the birth of light sheet microscopy, researchers now can perform complete 3D imaging characterization of intact samples. ...
Synaptive Medical, a global medical device and technology company solving surgical, imaging and data challenges, is pleased to announce the appointment of Timothy J. Scannell as the new Chair of the Board of Directors, effective June 20, 2023. Mr. Scannell joined Synaptive Medical’s Board of Directors in August 2022, bringing a wealth of experience and expertise in the medical device ...
Prior to joining Tris Pharma, he was the chief commercial officer at Aziyo Biologics, where he oversaw multiple business units, profitably negotiated commercial partnerships with distinguished organizations and was a key leader of the company’s successful IPO team. ...
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
ByeTheRNA
“We are pleased to partner with them to create a drug discovery platform that is biologically more relevant to researchers.” Ayla Annac, Co-founder and CEO of InvivoSciences comments, “We are especially proud and pleased to establish a long-term relationship with the leading developer and internationally-recognized manufacture of microplate ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
The senior management team contributes extensive industry knowledge and leadership in biologics drug discovery and development, data science, and business development. ...
A startup team from the University of Wisconsin that moved to San Diego in January to advance their technology for optimizing treatment regimens for cancer patients won the audience vote for best pitch at the EvoNexus Spring Demo Day last week. Lynx Biosciences founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer cells to determine ...
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wound. The ...
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh. This achievement follows a recent on-site inspection as part of the CAP’s Laboratory Accreditation Program. ...